PLCG1 and cancer: Analogous scenarios may be wide-spread in cancers where tyrosine kinases are constitutively active upon substitution, truncation, fusion, or overexpression—all conditions shown to activate PLC-γ1 (Arteaga et al., 1991; Peles et al., 1991).